Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16α-bromoepiandrosterone (HE2000)

Clinical Microbiology and Infection

Volumn 12, Issue 11, 2006, Pages 1082-1088

  Reading, C ^a   Dowding, C ^a   Schramm, B ^a   Garsd, A ^a   Onizuka Handa, N ^a   Stickney, D ^a   Frincke, J ^a  

^a Hollis Eden Pharmaceuticals Inc   (United States)

Author keywords

16 bromoepiandrosterone; AIDS; HE2000; Human immunodeficiency virus; Immune stimulation; Therapy

Indexed keywords

16ALPHA BROMOEPIANDROSTERONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD69 ANTIGEN; CYCLOOXYGENASE 2; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; PLACEBO; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; MONOTHERAPY; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33749078917     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01520.x     Document Type: Article

References (37)

1. Pedersen NC, North TW, Rigg R et al. 16alpha-Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression. Vet Immunol Immunopathol 2003; 94: 133-148.
2. Reddy M, Eirikis E, Davis C, Davis HM, Prabhakar U. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Meth 2004; 293: 127-142.
3. Donnenberg VS, O'Connell PJ, Logar AJ, Zeevi A, Thomson AW, Donnenberg AD. Rare-event analysis of circulating human dendritic cell subsets and their presumptive mouse counterparts. Transplantation 2001; 72: 1946-1951.
4. Testi R, Phillips JH, Lanier LL. T cell activation via Leu-23 (CD69). J Immunol 1989; 143: 1123-1128.
5. Biselli R, Matricardi PM, D'Amelio R, Fattorossi A. Multiparametric flow cytometric analysis of the kinetics of surface molecule expression after polyclonal activation of human peripheral blood T lymphocytes. Scand J Immunol 1992; 35: 439-447.
6. Mittag A, Lenz D, Gerstner AO et.al. Polychromatic (eight-color) slide-based cytometry for the phenotyping of leukocyte, NK, and NKT subsets. Cytometry A 2005; 65: 103-115.
7. Pang G, Buret A, Batey RT et al. Morphological, phenotypic and functional characteristics of a pure population of CD56+ CD16- CD3- large granular lymphocytes generated from human duodenal mucosa. Immunology 1993; 79: 498-505.
8. Loetscher P, Uguccioni M, Bordoli L et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998; 391: 344-345.
9. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997; 277: 2005-2007.
10. Schabenberger O. Introducing the GLIMMIX procedure for generalized linear mixed models. In: Proceedings of the 30th Annual SAS Users Group International Conference. Cary, NC: SAS Institute, Inc., 2005; 196-230.
11. Wright SC, Jewett A, Mitsuyasu R, Bonavida B. Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol 1988; 141: 99-104.
12. Aziz N, Nishanian P, Taylor JM et al. Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection. J Infect Dis 1999; 179: 843-848.
13. Breen EC, Rezai AR, Nakajima K et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990; 144: 480-484.
14. Sha BE, Valdez H, Gelman RS et al. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses 2002; 18: 661-665.
15. Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 2004; 31: 2055-2061.
16. Andrieu JM, Lu W. Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med 2004; 2: 17.
17. Siegal FP, Lopez C, Fitzgerald PA et al. Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptive components of cellular immunity. J Clin Invest 1986; 78: 115-123.
18. Macatonia SE, Lau R, Patterson S, Pinching AJ, Knight SC. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology 1990; 71: 38-45.
19. Pacanowski J, Kahi S, Baillet M et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001; 98: 3016-3021.
20. Nomura LE, deHaro ED, Martin LN, Maecker HT. Optimal preparation of rhesus macaque blood for cytokine flow cytometric analysis. Cytometry A 2003; 53: 28-38.
21. Nielsen SD, Afzelius P, Ersboll AK, Nielsen JO, Hansen JE. Expression of the activation antigen CD69 predicts functionality of in vitro expanded peripheral blood mononuclear cells (PBMC) from healthy donors and HIV-infected patients. Clin Exp Immunol 1998; 114: 66-72.
22. Sopper S, Sauer U, Muller JG, Stahl-Hennig C, ter Meulen V. Early activation and proliferation of T cells in simian immunodeficiency virus-infected rhesus monkeys. AIDS Res Hum Retroviruses 2000; 16: 689-697.
23. Giavedoni LD, Velasquillo MC, Parodi LM, Hubbard GB, Hodara VL. Cytokine expression, natural killer cell activation, and phenotypic changes in lymphoid cells from rhesus macaques during acute infection with pathogenic simian immunodeficiency virus. J Virol 2000; 74: 1648-1657.
24. Akari H, Mori K, Otani I et al. Induction of MHC-IIDR expression on circulating CD8+ lymphocytes in macaques infected with SIVmac239 nef-open but not with its nef-deletion mutant. AIDS Res Hum Retroviruses 1998; 14: 619-625.
25. Voiculescu C, Avramescu C, Radu E, Balasoiu M, Turculeanu A. Expression of activation surface markers, interleukin-2 synthesis and apoptosis rate in fresh or cultured lymphocytes from HIV-infected children. Roum Arch Microbiol Immunol 1998; 57: 33-44.
26. Tarazona R, DelaRosa O, Casado JG et al. NK-associated receptors on CD8 T cells from treatment-naive HIV-infected individuals: Defective expression of CD56. AIDS 2002; 16: 197-200.
27. Par G, Rukavina D, Podack ER et al. Decrease in CD3-negative-CD8dim (+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection. J Hepatol 2002; 37: 514-522.
28. Mosoian A, Teixeira A, Caron E, Piwoz J, Klotman ME. CD8+ cell lines isolated from HIV-1-infected children have potent soluble HIV-1 inhibitory activity that differs from beta-chemokines. Viral Immunol 2000; 13: 481-495.
29. Vitale M, Caruso A, Licenziati S et al. Differential production of IFN-gamma, analyzed at the single-cell level, by specific subsets of human NK and T cells from healthy and HIV (+) subjects. Cytometry 2000; 39: 189-194.
30. Semba RD, Tang AM. Micronutrients and the pathogenesis of human immunodeficiency virus infection. Br J Nutr 1999; 81: 181-189.
31. Marston B, De Cock KM. Multivitamins, nutrition, and antiretroviral therapy for HIV disease in Africa. N Engl J Med 2004; 351: 78-80.
32. Fawzi W. Micronutrients and human immunodeficiency virus type 1 disease progression among adults and children. Clin Infect Dis 2003; 37(suppl 2): 112S-116S.
33. Fawzi WW, Msamanga GI, Spiegelman D et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004; 351: 23-32.
34. Daynes RA, Dudley DJ, Araneo BA. Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur J Immunol 1990; 20: 793-802.
35. Suzuki T, Suzuki N, Daynes RA, Engleman EG. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol 1991; 6: 202-211.
36. Hernandez Pando R, Aguilar Leon D, Orozco H et al. 16α-bromoepiandrosterone restores T helper cell Type 1 activity and accelerates chemotherapy-induced bacterial clearance in model of progressive pulmonary tuberculosis. J Infect Dis 2005; 191: 299-306.
37. Freilich D, Ferris S, Wallace M et al. 16alpha-bromoepiandrosterone, a dehydroepiandrosterone (DHEA) analogue, inhibits Plasmodium falciparum and Plasmodium berghei growth. Am J Trop Med Hyg 2000; 63: 280-283.